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Abstract
Assessment of antibody responses to pneumococcal colonization in early childhood may aid our understanding of protection and inform
vaccine antigen selection. Serum samples were collected from mother-infant pairs during a longitudinal pneumococcal colonization study in
Burmese refugees. Maternal and cord sera were collected at birth and infants were bled monthly (1–24 months of age). Nasopharyngeal
swabs were taken monthly to detect colonization. Serum IgG titres to 27 pneumococcal protein antigens were measured in 2624 sera and
IgG to dominant serotypes (6B, 14, 19F, 19A and 23F) were quantiﬁed in 864 infant sera. Antibodies to all protein antigens were detectable
in maternal sera. Titres to four proteins (LytB, PcpA, PhtD and PhtE) were signiﬁcantly higher in mothers colonized by pneumococci at
delivery. Maternally-derived antibodies to PiuA and Spr0096 were associated with delayed pneumococcal acquisition in infants in univariate,
but not multivariate models. Controlling for infant age and previous homologous serotype exposure, nasopharyngeal acquisition of
serotypes 19A, 23F, 14 or 19F was associated signiﬁcantly with a ≥2-fold antibody response to the homologous capsule (OR 12.84, 7.52,
6.52, 5.33; p <0.05). Acquisition of pneumococcal serotypes in the nasopharynx of infants was not signiﬁcantly associated with a ≥2-fold rise
in antibodies to any of the protein antigens studied. In conclusion, nasopharyngeal colonization in young children resulted in demonstrable
serum IgG responses to pneumococcal capsules and surface/virulence proteins. However, the relationship between serum IgG and the
prevention of, or response to, pneumococcal nasopharyngeal colonization remains complex. Mechanisms other than serum IgG are likely to
have a role but are currently poorly understood.
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Background
Nasopharyngeal colonization is thought to always precede
pneumococcal infection [1]. Immune responses to colonization
are complex: experimental murine models suggest a limited
role for antibody and that an IL-17A-mediated CD-4+ T-cell
pathway is the dominant mechanism involved in immunity to
pneumococcal colonization [2,3]. However, coloniza-
tion-related serum immunoglobulin G (IgG) antibody
responses to capsular polysaccharide and surface/virulence
proteins have been described in adult humans [4,5], although
these antibodies may not protect against colonization [6]. In
children aged <2 years, studies have demonstrated limited
serum anti-capsular antibody development in the absence of
pneumococcal immunization [7]. Several pneumococcal pro-
teins are immunogenic in young children and antibody
development is correlated with pneumococcal exposure [8].
Most studies in the literature use relatively infrequent sampling
of blood to assess development of natural immunity, few
combine with nasopharyngeal carriage data, and none to our
knowledge have ever sampled monthly for 24 months and
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then performed combined analyses of anti-capsular and
anti-protein antibody responses.
Vaccines containing pneumococcal proteins have provided
protection against invasive infections in mice [9]. Assessments
of the relationship between nasopharyngeal colonization and
antigen-speciﬁc immune responses in young children are
critical for prediction of potential carriage-mediated protein
vaccine hyporesponsiveness. This is important because sero-
type-speciﬁc hyporesponsiveness has been previously demon-
strated for the currently available conjugate vaccines [10].
This manuscript describes the temporal relationships
between nasopharyngeal colonization and serum IgG to
pneumococcal capsular polysaccharides and surface/virulence
proteins over the ﬁrst 2 years of life in a population where
there is early/sustained pneumococcal carriage. Effects of
transplacentally-transferred IgG antibodies on infant pneumo-
coccal colonization are explored.
Methods
Study population
Mother-infant pairs were followed from birth for 24 months
during a pneumococcal colonization and pneumonia study in a
camp for Burmese refugees [11,12]. At delivery, nasopharyn-
geal swab (NPS) and serum specimens were collected from the
mother and a serum specimen from the umbilical cord. NPS
were taken from mother to infant, plus serum from infants, at
monthly intervals (1–24 months of age). Pneumococcal vac-
cines were not available to the study population.
Pneumococcal nasopharyngeal colonization
Nasopharyngeal swabs were cultured using the WHO
standard protocol to detect pneumococcal colonization
[13]. Brieﬂy, a Dacron-tipped nasopharyngeal swab was used
to sample the nasopharynx and the tip immediately excised
into a cryotube containing 1 mL STGG (skim milk, tryptone,
glucose, glycerol) transport medium. NPS-STGG specimens
were transferred back to the laboratory in a cool box before
being promptly frozen at80°C. Ten microlitres of the
thawed and vortexed NPS-STGG specimen were cultured
overnight on sheep blood-CNA agar (bioMerieux, Marcy
L’Etoile, France) at 36°C and 5% CO2. All morphologically
distinct alpha-haemolytic colonies were subcultured onto
plain sheep blood agar (Clinical Diagnostics, Bangkok, Thai-
land) and S. pneumoniae was conﬁrmed by colonial morphol-
ogy and susceptibility to optochin (Oxoid, Basingstoke, UK).
The bile solubility test was used to conﬁrm isolates with
equivocal optochin disc susceptibility and those non-typeable
by Omniserum (SSI Diagnostica, Hillerod, Denmark). Pneu-
mococcal isolates were serotyped by latex agglutination using
a full panel of pneumococcal antiserum (SSI Diagnostica), with
Quellung conﬁrmation of equivocal results [14].
Antigens and serological methods
Serum IgG antibodies to 27 pneumococcal protein antigens
were measured using a direct binding electrochemilumines-
cence-based multiplex assay (Table 1). The assay was based on
that described for pneumococcal polysaccharide antigens
utilizing MesoScale Discovery (MSD, Rockville, MD, USA)
technology [15]. Pneumococcal reference serum 007 was used
TABLE 1. Protein antigens assessed in the study
Name Internal ID Protein details Provided by
CbpA PP01 Choline binding protein A, without choline binding domain (CbpA NR1XR2P) GSK
LytB PP11 Endo-beta-N-acetylglucosaminidase (LytB-T-PO1) Sanoﬁ Pasteur
LytC PP02 Lysozyme (LytC C-ter) GSK
NanA PP33 Neuraminidase (NanA) UAB
PcpA PP13 Choline binding protein (PcpA DC6842) Sanoﬁ Pasteur
PcsB-1 PP06 Secreted 45 kDa protein (PcsB, SP2216-1) Intercell
PcsB-2 PP32 Secreted 45 kDa protein (PcsB, Spr2021) Novartis
PhtD-1 PP03 Pneumococcal histidine triad D (PhtD) GSK
PhtD-2 PP14 Pneumococcal histidine triad protein (PhtD DC6857) Sanoﬁ Pasteur
PhtE PP10 Truncated histidine triad protein (PhtE-T1 DC6286) Sanoﬁ Pasteur
PiaA PP09 Part of iron uptake ABC transporter (PiaA) PATH
PiuA PP08 Part of iron uptake ABC transporter (PiuA) PATH
Ply-1 PP12 Pneumolysin (WtPly DC6968) Sanoﬁ Pasteur
Ply-2 PP17 Pneumolysin (P10V12/13 Ply) UAB
PsaA PP04 Pneumococcal surface adhesin A (PsaA, SP1650) Intercell
PspA-Fam1 PP16 Pneumococcal surface protein A, family 1 (PspA, P18-01/P18-02) UAB
PspA-Fam2 PP15 Pneumococcal surface protein A, family 2 (PspA, UAB099 P9V63) UAB
RrgA-T4 PP22 RrgA pilus subunit, adhesin (RrgA, T4) Novartis
RrgB-T4 PP18 RrgB pilus subunit, backbone (RrgB, T4) Novartis
RrgB-6B PP19 RrgB pilus subunit, backbone (RrgB, 6B) Novartis
RrgB-23F PP20 RrgB pilus subunit, backbone (RrgB, 23F) Novartis
StkP PP05 Serine threonine kinase protein (StkP, SP1732-3) Intercell
StrH PP29 Beta-N-acetylhexosaminidase (StrH, Spr0057) Novartis
SP0609 PP31 Amino acid ABC transporter, amino acid-binding protein Intercell
SP2027 PP07 Conserved hypothetical protein (Spr1/SP2027) Intercell
SP2194 PP30 ATP-dependent Clp protease, ATP-binding subunit Intercell
Spr0096 PP24 LysM domain-containing protein Novartis
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as a standard on each plate and assigned a value of 1000
arbitrary units for each antigen [16]. Antibody levels in sera
from study participants were expressed as a titre with
reference to the amount in 007.
Serum IgG antibody concentrations to capsular polysaccha-
rides 6B, 14, 19F, 19A and 23F were determined by
enzyme-linked immunosorbent assay, after adsorption with
22F polysaccharide and cell-wall polysaccharide [17]. The assay
limit of detection was 0.15 mg/L; results below this were
reported as 0.075 mg/L. Serotypes were selected on the basis
of inclusion in the 13-valent conjugate vaccine (PCV13) and
frequency of carriage in the cohort [11].
Serum specimens
For anti-protein antibody analyses, all mother and cord blood
specimens were included. Infant specimens were selected for
anti-protein antibody analyses to obtain good coverage at each
sampling point during the ﬁrst year of life and to include
time-points from the second year of life with the largest
specimen numbers. For anti-capsular antibody analyses, spec-
imens from infants with complete 24-month sets of both NPS
and serum specimens were selected.
Statistical analysis
Data were analysed using Stata/IC 12.1 (StataCorp, College
Station, TX, USA). Antibody concentrations/titres were
log-transformed prior to analyses. Student’s t-test or ANOVA
were used to compare groups, with Bonferroni adjustment for
multiple comparisons. Proportions were compared using the
chi-squared test. The impact of maternally-derived antibodies
on the timing of pneumococcal acquisition in infants was
explored by survival analysis.
To assess serum antibody responses in relation to
nasopharyngeal pneumococcal acquisitions, a subset of infant
data was analysed. Pneumococcal acquisitions were deﬁned
as the ﬁrst appearance of a serotype (including non-typeable
pneumococci as a ‘type’) in the nasopharynx or the
reappearance of the serotype following its absence from
≥2 consecutive NPS. In cases of multiple serotype coloni-
zation, all serotypes were considered in the analyses. For
each sampling time-point, ratios of antibody concentrations/
titres were calculated by dividing the current specimen
concentration/titre by the preceding month’s concentration/
titre. Assessment of receiver-operating characteristic curves
for these ratios vs. acquisitions did not reveal a meaningful
response cut-off value. Therefore a 2-fold or greater rise in
antibody concentration/titre was arbitrarily used to deﬁne a
‘response’. Generalized estimating equations with a logistic
link and exchangeable correlation structure were used to
determine odd ratios (ORs) for an antibody response at
each time-point, controlling for age and pneumococcal
acquisitions.
Ethics
Ethical approval was granted by the Faculty of Tropical
Medicine, Mahidol University (MUTM-2009-306) and Oxford
University (OXTREC-031-06).
Results
Serum specimens from 230 mothers and 222 infants were
included in these analyses (n = 2624; Table S1).
Maternal anti-protein antibody titres/transplacental transfer
Twenty per cent (46/229) of mothers were colonized by
pneumococci at delivery. Every mother had measurable serum
IgG antibodies to all proteins studied. Geometric mean
antibody titres (GMT) to four proteins were signiﬁcantly
higher in colonized women compared with non-colonized
women: LytB (1093.5 vs. 747.9, p 0.0002); PcpA (1264.4 vs.
981.3, p 0.04); PhtD (PhtD-1 (830.3 vs. 613.7, p 0.02); PhtD-2
(758.1 vs. 576.4, p 0.02)); PhtE (789.0 vs. 571.3, p 0.02).
In 183 mother-cord blood pairs, effective transplacental
antibody transfer was demonstrated: mean cord:mother
serum IgG titre ratios were 0.77–1.08 (data not shown).
Maternal anti-protein antibody titres/time to infant
pneumococcal acquisition
Effects of cord serum antibody titres on timing of ﬁrst
pneumococcal acquisition were explored in 179 infants. Age at
ﬁrst pneumococcal acquisition was 45.5 days (median;
inter-quartile range (IQR) 15.5–76.5). All but one infant had
been colonized by 11 months.
In univariate Cox proportional hazards models, higher
serum IgG antibody titres to PiuA and Spr0096 were
associated signiﬁcantly with delayed pneumococcal acquisi-
tion (PiuA, hazard ratio (HR) 0.68, 95% conﬁdence interval
(CI) 0.46–0.98, p 0.04; Spr0096, HR 0.73, 95% CI 0.57–0.95,
p 0.02). There was no evidence of higher cord blood
anti-protein antibody titres being signiﬁcantly associated with
earlier pneumococcal acquisition (Table S2). In a multivariate
model including environmental/household factors, cord
blood antibody titres to PiuA (HR 0.70, 95% CI 0.45–1.08,
p 0.1) or Spr0096 (HR 0.82, 95% CI 0.62–1.09, p 0.2) were
no longer associated signiﬁcantly with timing of pneumo-
coccal acquisition. In this model, maternal smoking (HR 1.49,
95% CI 1.01–2.21, p 0.046) was associated with a signiﬁ-
cantly earlier acquisition age, with similar trends for
maternal pneumococcal colonization (HR 1.49, 95% CI
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1.00–2.25, p 0.05) and young children in the household (HR
1.39, 95% CI 0.99–1.96, p 0.06). Infants born in the wet
season acquired pneumococci later than those born in the
hot or cool seasons (HR 0.62, 95% CI 0.40–0.95, p 0.03)
(Table S2).
Anti-protein antibody kinetics in infants
In 222 infants studied, 40.3% were colonized by pneumococci
at 1 month and 66.4–88.0% were colonized at each subse-
quent visit. One infant was not colonized by 24 months of age.
Of the 3205 pneumococci cultured from these infants, 1786
(55.7%) were PCV13 serotypes, 1084 (33.8%) were non-vac-
cine serotypes and 335 (10.5%) were non-typeable. Geometric
mean serum IgG antibody titres to all proteins fell rapidly after
birth to a nadir at 4 months (median; IQR 3–5) (Fig. 1).
Subsequently, GMTs increased and this was largely in response
to pneumococcal exposure (Figure S1). Ratios of GMT at birth
(cord blood) to 12 months of age were 0.03–1.08. Twelve--
month GMTs had reached cord blood levels (ratio ≥1.0) for
PsaA, SP0609, SP2027 and SP2194. GMT ratios for cord and
24-month specimens were 0.10–2.00. The GMT ratio was >1.0
for seven proteins (LytC, NanA, PcsB (PcsB-1/2), SP0609,
SP2027, SP2194 and Spr0096) and <0.5 for another seven
(CbpA, PhtE, Ply-2, PspA (PspA-Fam1/Fam2), RrgA-T4,
RrgB-23F and StkP). Evidence of increases in speciﬁc IgG in
the absence of detectable colonization was seen for certain
proteins, including pneumolysin (Figure S1).
Antibody responses to pneumococcal acquisitions in infants
Thirty-six of the infants had complete 24-month swab/serum
collections: median age at pneumococcal acquisition was
45.5 days; all 36 infants had been colonized by 7 months
(Figure S2). Pneumococci were detected in 20 swabs per infant
(median; IQR 16–21). Infants were colonized by seven
individual serotypes (median; IQR 6–8). One hundred and six
out of 305 (34.8%) pneumococcal nasopharyngeal acquisitions
were of serotypes 6B, 14, 19F, 19A and 23F: 35/36 infants
(97.2%) carried at least one of these serotypes and 23/36
(63.8%) carried ≥2. Serotype 19A was acquired later than the
other serotypes (p 0.03; Figure S3).
Serum anti-capsular IgG were highest in the ﬁrst infant
sample, reﬂecting maternally-derived antibodies. Antibody
concentrations declined until 6 months of age, with signiﬁcant
variation between serotypes (p 0.02) (Fig. 2, Table 2). Fol-
FIG. 1. Kinetics of serum IgG antibodies to 27 pneumococcal protein
antigens in infants. The graphs show monthly antibody data for 222
infants from birth to 24 months of age (GMTs with 95% conﬁdence
intervals).
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lowing this nadir, IgG concentrations increased modestly: none
of the geometric mean concentrations (GMC) at 24 months
were equal to the 1-month values (Table 2). Between 6 and
24 months of age, the greatest increase was seen in anti-19A
antibodies (mean fold-change, 4.91; 95% CI, 3.31–7.28) and the
smallest in anti-14 antibodies (mean fold-change, 0.91; 95% CI,
0.54–1.52) (p <0.001). At 24 months, measurable anti-capsular
IgG antibodies were found in the sera of 19.4–97.1% of infants,
varying by serotype (Table 2). Serum anti-capsular IgG
concentration of ≥0.35 mg/L may protect against invasive
disease caused by the homologous serotype [18,19]. By
24 months of age the proportion of infants with anti-capsular
IgG concentrations above this threshold varied considerably by
serotype: 5.6% (95% CI, 0.1–18.7) for 23F, 30.6% (95% CI,
16.3–48.1) for 19F, 33.3% (95% CI, 18.6–60.0) for 6B, 38.9%
(95% CI, 23.1–56.5) for 14, and 85.7% (95% CI, 67.2–93.6) for
19A (p <0.001). Serum anti-capsular IgG concentrations of
≥5.0 mg/L may be required to protect against nasopharyngeal
colonization [4]. By 24 months this concentration was only
achieved by three infants (8.3%) for a single serotype, 19A.
Serum specimens taken at 1 month of age were used to
assess the contribution of maternally-derived antibodies to the
risk/timing of nasopharyngeal acquisition by the homologous
serotype over the ﬁrst 2 years of life: no signiﬁcant associa-
tions were detected (Table 3). Anti-protein antibody kinetics
in these infants were similar to the larger cohort (Figure S4).
In a univariate analysis, the proportion of pneumococcal
acquisitions resulting in a ≥2-fold homologous anti-capsular
IgG response varied by serotype: 11.1% (2/18) for 6B, 15.4%
(4/26) for 23F, 23.1% (3/13) for 14, 25.0% (9/36) for 19F, and
50.0% (4/8) for 19A. Controlling for age and previous
homologous serotype exposure, nasopharyngeal acquisition
of serotypes 19A, 23F, 14 or 19F was associated signiﬁcantly
with a ≥2-fold antibody response to the homologous capsule
(OR, 12.84, 7.52, 6.52, 5.33; p <0.05) (Table 4). This was not
the case for acquisitions of serotype 6B (p 0.3). Acquisition of
a heterologous serotype was not associated with a ≥2-fold rise
TABLE 2. Geometric mean serum anti-capsular IgG antibody concentrations in 36 infants sampled over the ﬁrst 2 years of life
Serotype
GMC (95% CI), mg/L
Infants with detectable
IgG at 24 months, N (%)1 month 6 months 12 months 18 months 24 months
6B 0.71 (0.48–1.04) 0.09 (0.07–0.10) 0.11 (0.08–0.13) 0.17 (0.13–0.22) 0.24 (0.18–0.32) 28/36 (77.8)
14 3.74 (275–5.08) 0.23 (0.16–0.33) 0.16 (0.11–0.23) 0.20 (0.14–0.30) 0.21 (0.14–0.32) 18/36 (50.0)
19F 0.90 (0.63–1.27) 0.10 (0.08–0.12) 0.13 (0.09–0.18) 0.20 (0.14–0.29) 0.21 (0.14–0.31) 16/36 (55.6)
19A 1.58 (1.19–2.11) 0.20 (0.15–0.26) 0.41 (0.28–0.60) 0.80 (0.54–1.17) 0.95 (0.67–1.35) 34/35 (97.1)
23F 0.52 (0.36–0.74) 0.08 (0.08–0.08) 0.09 (0.07–0.11) 0.11 (0.09–0.14) 0.10 (0.08–0.12) 7/36 (19.4)
Detectable IgG was deﬁned as an anti-capsular IgG concentration of ≥0.15 mg/L.
TABLE 3. Assessment of the effect of maternally derived
serum anti-capsular IgG antibodies on the risk and timing of
nasopharyngeal acquisition of the homologous serotype in




OR (95% CI) p-Value
Timing of
acquisition
HR (95% CI) p-Value
6B 1.06 (0.23–4.91) 0.9 0.99 (0.32–3.11) 1.0
14 0.54 (0.07–3.85) 0.5 0.65 (0.14–3.00) 0.6
19F 0.64 (0.11–3.63) 0.6 0.77 (0.32–1.81) 0.5
19A 9.86 (0.46–213.16) 0.1 6.49 (0.46–91.35) 0.2
23F 1.91 (0.37–9.75) 0.4 1.41 (0.46–4.34) 0.5
Logged serum anti-capsular IgG concentrations in the infant specimen collected at
1 month of age were compared with homologous serotype acquisition in
univariate logistic regression and Cox proportional hazards models. An OR of
<1 indicated a lower risk of nasopharyngeal acquisition with increasing concen-
trations of anti-capsular IgG. An HR of <1 indicated a longer interval to acquisition
with increasing concentrations of anti-capsular IgG.
FIG. 2. Kinetics of serum IgG antibodies to
ﬁve pneumococcal capsular polysaccharides.
The graph shows monthly antibody data for
36 infants from 1 to 24 months of age (GMCs
with 95% conﬁdence intervals).
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in anti-capsular antibodies to these serotypes (Table 4). In
contrast, acquisition of pneumococcal serotypes in the naso-
pharynx was not signiﬁcantly associated with a ≥2-fold rise in
antibodies to any of the protein antigens (Table 5). The
proportion of pneumococcal acquisitions associated with a
≥2-fold antibody response ranged from 3.1% (RrgB-23F) to
12.9% (SP0609) (data not shown).
Discussion
This manuscript describes the development of serum IgG to a
large panel of pneumococcal surface/virulence proteins, and
the effect of transplacental transfer of these antibodies, in a
population of SE Asian infants where pneumococcal coloniza-
tion occurs early in life. Comparison of anti-protein antibody
with anti-capsular antibody responses was made.
Maternally-derived serum IgG antibodies to the pneumo-
coccal proteins studied did not appear to protect infants from
early pneumococcal colonization. In a multivariate model, only
environmental factors signiﬁcantly inﬂuenced the timing of
infant colonization. Studies from the Philippines and Papua
New Guinea concluded that maternally derived anti-pneum-
olysin antibodies were associated with delayed infant coloni-
zation [20,21]. Reproducing the logistic regression analysis
described in the Philippines study did demonstrate a trend
towards delayed colonization with higher anti-Ply titres in our
cohort (data not shown), but the Cox model remained a more
appropriate analysis for the current dataset. Differences in
environmental factors, nasopharyngeal sampling frequency or
assay/statistical methodology may account for the differences
between studies.
We found no evidence that maternally-derived anti-capsular
antibodies delayed or prevented colonization in infants. None
of the 1 month of age anti-capsular IgG GMCs were close to
the putative protective threshold of 5 mg/L [4]. Anti-capsular
IgG concentrations ≥5 mg/L were only achieved in three
infants by 24 months, also suggesting that serum anti-capsular
IgG is unlikely to protect against colonization in non-PCV
immunized young children [22].
The absence of a protective effect of antibody on coloni-
zation may reﬂect the likely high level of exposure to
pneumococci in the community in this population but has also
been documented in European studies [4,23,24]. These
ﬁndings were also in agreement with a murine study, which
concluded that serum antibodies to PsaA, PspA or PpmA were
not protective against nasopharyngeal colonization [25].
However, these results do not necessarily predict the
protective quality of the immune response elicited by active
immunization against any of the antigens.
Infants began developing serum antibodies to selected
proteins from 2 months of age and to capsular polysaccharides
from 6 months of age, largely in response to nasopharyngeal
colonization. Pneumococcal acquisitions were more likely to
result in a clear homologous anti-capsular IgG response rather
than anti-protein responses. However, certain proteins were
clearly more immunogenic than others. Antibodies to PsaA
rose rapidly from 2 months and the GMT at 12 months was
greater than the cord blood GMT, in agreement with previous
studies [20,26]. A small number of proteins were poorly
immunogenic throughout the study period. Although antibod-
ies to pneumococcal pilus proteins (RrgA, B and C) are highly
protective against invasive disease in mice [27], antibody
TABLE 5. Effect of pneumococcal colonization events on
serum IgG anti-protein antibody responses in 36 infants
sampled over the ﬁrst 2 years of life
Protein antibody Colonization, OR (95% CI) p-Value
CbpA 1.04 (0.66–1.65) 0.9
LytB 0.92 (0.44–1.92) 0.8
LytC 0.79 (0.39–1.58) 0.5
NanA 1.20 (0.71–2.01) 0.5
PcpA 1.01 (0.66–1.56) 1.0
PcsB-1 0.71 (0.44–1.14) 0.2
PcsB-2 0.64 (0.39–1.05) 0.08
PhtD-1 1.41 (0.84–2.35) 0.2
PhtD-2 1.24 (0.78–2.00) 0.9
PhtE 1.25 (0.78–2.00) 0.4
PiaA 1.05 (0.64–1.70) 0.9
PiuA 1.33 (0.81–2.18) 0.3
Ply-1 1.46 (0.78–2.76) 0.2
Ply-2 1.48 (0.80–2.76) 0.2
PsaA 1.34 (0.76–2.39) 0.3
PspA-Fam1 1.30 (0.84–2.04) 0.2
PspA-Fam2 1.18 (0.75–1.84) 0.5
RrgA-T4 1.23 (0.61–2.45) 0.6
RrgB-T4 0.73 (0.42–1.28) 0.3
RrgB-6B 0.76 (0.45–1.29) 0.3
RrgB-23F 0.62 (0.29–1.34) 0.2
StkP 1.06 (0.59–1.90) 0.8
StrH 1.46 (0.84–2.54) 0.2
SP0609 1.23 (0.79–1.93) 0.4
SP2027 0.81 (0.43–1.54) 0.5
SP2194 0.64 (0.32–1.31) 0.2
Spr0096 0.81 (0.47–1.39) 0.5
The results are summarized as the age-adjusted odds ratios (95% CI) for a ≥2-fold
rise in antibody titre in response to acquisition of pneumococci in the
nasopharynx.
TABLE 4. Effect of pneumococcal colonization events on
serum IgG anti-capsular antibody responses in 36 infants





OR (95% CI) p-Value
Heterologous
colonization,
OR (95% CI) p-Value
6B 2.48 (0.53–11.68) 0.3 1.43 (0.78–2.60) 0.2
14 6.52 (1.73–24.54) 0.006 0.53 (0.24–1.17) 0.1
19F 5.33 (2.35–12.10) <0.001 1.19 (0.67–2.11) 0.6
19A 12.84 (3.01–54.82) 0.001 1.28 (0.77–2.14) 0.3
23F 7.52 (2.21–25.60) 0.001 1.17 (0.45–3.01) 0.7
The results are summarized as the odds ratio (95% CI) for a ≥2-fold rise in
antibody concentration in response to acquisition of pneumococci in the
nasopharynx. Heterologous serotype acquisition was deﬁned as the acquisition
of any other pneumococcal type, including non-typeable strains. Age and previous
carriage of the homologous serotype were adjusted for in the model.
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responses to pilus following colonization were relatively
modest, probably reﬂecting the non-conserved nature of the
pilus-encoding genes amongst pneumococci [28]. We previ-
ously demonstrated a PI-1 prevalence of 35.2% in carried
pneumococci from this cohort [29].
At 24 months a proportion of infants had serum anti-cap-
sular IgG concentrations above the putative protective
threshold for invasive disease (0.35 mg/L), from 5.6% (23F)
to 85.7% (19A). These data support the hypothesis that,
although anti-capsular antibodies are an important defence
against invasive pneumococcal infection, other immune mech-
anisms, perhaps mucosal antibody produced by mucosal B cells
or T cells, are also critical for the observed decline in incidence
of invasive disease caused by all common serotypes after the
ﬁrst year of life [30].
The early acquisition and persistence of pneumococcal
colonization in the nasopharynx of the study infants were
both important positive and negative aspects of our study.
After 3 months of age >2/3 of infants were colonized at each
time-point, permitting determination of the kinetics of serum
IgG development to pneumococcal antigens in a population
almost continually exposed to the organism. In terms of
pneumococcal colonization, this population is similar to many
developing world settings where effective pneumococcal
vaccines with broad serotype coverage will have the most
beneﬁt. However, this high level of colonization, coupled with
the monthly swabbing interval, limited the ability to detect
small differences in the timing of ﬁrst pneumococcal acqui-
sition in relation to cord blood antibody titres. In Papua New
Guinea weekly swabs were taken from infants during the ﬁrst
month of life, resulting in a higher resolution than we
achieved [21].
In conclusion, our results demonstrate a considerable
variation in the immunogenicity of pneumococcal surface/
virulence proteins in infancy. Acquisition of pneumococci in
the nasopharynx resulted in demonstrable anti-capsular, but
not anti-protein, responses. Evidence of antibody-mediated
protection against colonization was not identiﬁed. Further
work on the immunological mechanisms underlying protection
from nasopharyngeal acquisition is required.
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